Status:
COMPLETED
Danshu Capsule and Ursodeoxycholic Acid Capsule in Preventing Recurrence of Choledocholithiasis
Lead Sponsor:
First People's Hospital of Hangzhou
Conditions:
Choledocholithiasis
Recurrence
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
\[objective\] to compare the efficacy of Danshu capsule and ursodeoxycholic acid (UDCA) in preventing recurrence of choledocholithiasis after operation. \[methods\] one hundred and fifty ERCP patients...
Eligibility Criteria
Inclusion
- inclusion criteria:
- Choledocholithiasis was diagnosed by B-ultrasound / CT/MRCP, The patients are generally in good condition, no surgical taboos, and can tolerate general anesthesia and ERCP surgery.
- Agree to participate in the project research, know the benefits and possible risks of surgery, know the benefits and risks of drugs, and sign an informed consent form.
- exclusion criteria：
- patients with cholecystolithiasis, hepatitis B, biliary ascariasis, liver cirrhosis, hemolytic anemia, congenital jaundice and tumor were excluded.
- Excluding serious primary diseases such as heart, brain, lung, kidney and blood system.
- Those who are allergic or allergic to drugs in this test are excluded.
- Pregnancy vibration or nursing women were excluded.
Exclusion
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04484870
Start Date
March 1 2017
End Date
July 20 2019
Last Update
July 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hangzhou first people's Hospital
Hangzhou, Zhejiang, China, 310000